Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer
A phase 2 trial of gemcitabine, cisplatin, oxaliplatin and capecitabine in gallbladder cancer and other biliary tract cancers, run by Qilu Pharmaceutical Co., Ltd., not yet recruiting.
Overview
Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer is a phase 2 interventional study registered as NCT07151872 by Qilu Pharmaceutical Co., Ltd., with a registry enrolment figure of 120 participants, started 2025-09 and due to reach its primary completion in 2026-10. Interventions recorded: QLS31905 for Injection, Gemcitabine Hydrochloride for Injection, Cisplatin for Injection, QL2107 Injection, Oxaliplatin Injection, Capecitabine Tablets. Conditions listed: CLDN18.2-positive Advanced Biliary Tract Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialTuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract Cancer
Shares Oxaliplatin, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
- TrialA Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
Shares Oxaliplatin, Capecitabine, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents and the tag gallbladder-deep-dive.
- TrialHepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma
Shares Oxaliplatin, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Gemcitabine and the tag gallbladder-deep-dive.
- TrialCTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Biliary tract cancer (all types), Gemcitabine and the tag gallbladder-deep-dive.
- TrialPrecision Integrated Strategies and Efficacy Evaluation for Biliary Tract Cancers: An Umbrella Platform Study
Shares Oxaliplatin, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
- TrialQL1706（Iparomlimab/Tuvonralimab) Combined With Gemcitabine and Cisplatin as First-Line Treatment for PD-L1-Positive Biliary Tract Cancer
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Biliary tract cancer (all types), Gemcitabine and the tag gallbladder-deep-dive.
- TrialMulticenter Phase 2 Study of Envafolimab in Biliary Tract Cancers
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Biliary tract cancer (all types), Gemcitabine and the tag gallbladder-deep-dive.
- TrialGemcitabine-Cisplatin Plus Envafolimab in Resectable Biliary Tract Malignancies
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Biliary tract cancer (all types), Gemcitabine and the tag gallbladder-deep-dive.